Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.86 USD | 0.00% | -11.43% | -36.95% |
May. 09 | BioXcel Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
May. 09 | Transcript : BioXcel Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024 |
Business Summary
Number of employees: 74
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Neuroscience and Immuno-oncology Drugs
100.0
%
| 0 | 100.0 % | 1 | 100.0 % | +268.00% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 0 | 100.0 % | 1 | 100.0 % | +268.00% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Vimal Mehta
FOU | Founder | 63 | 17-03-28 |
Director of Finance/CFO | 66 | 17-09-30 | |
Frank Yocca
CTO | Chief Tech/Sci/R&D Officer | 68 | 17-05-31 |
Vincent O'Neill
CTO | Chief Tech/Sci/R&D Officer | 55 | 17-06-30 |
Brennan Doyle
IRC | Investor Relations Contact | - | - |
Chetan Lathia
LAW | General Counsel | - | - |
Matthew Wiley
PRN | Corporate Officer/Principal | 52 | 22-01-18 |
Javier Rodriguez
LAW | General Counsel | 52 | 21-02-22 |
55 | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Michael Miller
BRD | Director/Board Member | 67 | 22-06-30 |
Peter Mueller
CHM | Chairman | 68 | 17-03-31 |
Sandeep Laumas
BRD | Director/Board Member | 56 | 17-08-31 |
Vimal Mehta
FOU | Founder | 63 | 17-03-28 |
55 | - | ||
Michal Votruba
BRD | Director/Board Member | 58 | 19-03-06 |
June Bray
BRD | Director/Board Member | 70 | 21-02-28 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 37,530,821 | 28,498,380 ( 75.93 %) | 0 | 75.93 % |
Company contact information
BioXcel Therapeutics, Inc.
555 Long Wharf Drive 12th floor
06511, New Haven
+475 238 6837
http://www.bioxceltherapeutics.comSector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-36.95% | 69.81M | |
+9.83% | 118B | |
+10.80% | 106B | |
-10.84% | 23.4B | |
-1.69% | 22.1B | |
-10.23% | 18.34B | |
-41.92% | 16.59B | |
-15.11% | 15.97B | |
+6.62% | 14.03B | |
+17.53% | 11.67B |
- Stock Market
- Equities
- BTAI Stock
- Company BioXcel Therapeutics, Inc.